Profilaxia pré exposição: uma revisão narrativa dos ensaios clínicos como medida preventiva a epidemia do HIV
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
Acquired Immune Disease Syndrome, also known as AIDS (Acquired
Immunodeficiency Syndrome), is a sexually transmitted disease that is caused later
by a more advanced stage of HIV. The human immunodeficiency virus belongs to the
Retroviridae family, the Orthoretrovirinae subfamily, and the Lentivirus genus. The
virus is characterized by being human only, that is, it does not have its reservoir in
another animal and its R0 (basic reproduction rate) is approximately 4 people. There
is no cure for HIV, however, it can be controlled by treatment regimens consisting of a
combination of antiretroviral (ARV) drugs. HIV Pre-Exposure Prophylaxis (PrEP) is
one of the biomedical interventions that provides safety to the risk behavior and has
been gaining great adherence along with the most advanced studies. CAB-LA has
emerged as a new and positive alternative and extremely efficient, which together
with other prevention tools, can help reduce the number of new cases. Among other
drugs, we can consider tenofovir disoproxil fumarate associated with emtricitabine
and the recent lecanapavir, which are other alternatives with promising research and
considered as new tools for the use of PrEP.
Description
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

